Adherence to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study
Table 1
Baseline clinical characteristics of 2000 patients with valvular and nonvalvular atrial fibrillation.
Clinical features
Valvular AF (, 8.9%)
Nonvalvular AF (, 91.1%)
value
Age in years ()
<0.001
years
27 (15.3%)
165 (9.1%)
<0.001
years
18 (10.2%)
533 (29.2%)
<0.001
Females
118 (66.7%)
949 (52.1%)
<0.001
Hypertension
95 (53.7%)
1391 (76.3%)
<0.001
Diabetes mellitus
55 (31.1%)
827 (45.4%)
<0.001
104 (65.8%)
1288 (77.3%)
0.002
Hypercholesterolemia
49 (27.7%)
829 (45.5%)
<0.001
Current cigarette smoking
26 (14.7%)
247 (13.6%)
0.65
Permanent atrial fibrillation
83 (46.9%)
521 (28.6%)
<0.001
Stroke or systemic embolization
27 (15.3%)
298 (16.3%)
0.83
Ischemic heart disease
13 (7.3%)
212 (11.6%)
<0.001
Heart failure
33 (18.6%)
434 (23.8%)
0.14
16 (9.2%)
229 (13.4%)
0.15
Pulmonary hypertension
79 (44.6%)
264 (25.5%)
<0.001
Left ventricular hypertrophy
54 (33.8%)
653 (39.6%)
0.09
Sleep apnea
3 (17%)
73 (4.0%)
0.15
Chronic lung disease
6 (3.4%)
79 (4.3%)
0.64
Chronic kidney disease
11 (6.2%)
170 (9.3%)
0.22
HAS-BLED score ()
0.004
Body mass index was measured in 1824 patients, left ventricular ejection fraction in 1888 patients, pulmonary hypertension in 1998 patients, and left ventricular hypertrophy in 1808 patients.
